Issue Date: October 24, 2011
Abbott Will Split Into Two Companies
Abandoning its structure as a diversified health care company, Abbott Laboratories will split into separate medical products and research-based drug companies. The medical products company will have annual sales of about $22 billion. It will include Abbott’s nutritional products, diagnostics, medical devices, and branded-generics businesses and will retain the Abbott name. The pharmaceutical firm, to be named later, will have annual sales of about $18 billion. Leading products will include Humira, Lupron, Synagis, Kaletra, Creon, and Synthroid.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society